5 Topic Commentaries

Urine Bladder Cancer Test Could Triage Cystoscopy

Urine Bladder Cancer Test Could Triage Cystoscopy

• 

  William G. Nelson, MD, PhD, DSc

  Oncology

  •

  Johns Hopkins Medicine

  It's common enough that we can't do cystoscopy on everybody. Some aspects of it have changed. There were times when blood in the urine might reflect kidney stones and stuff and so there's a bunch of clinical scenarios you want to be able to dissect and to use things that are scalable to offices and to even home tests ultimately perhaps it's going to be very helpful.

  Source
• 

  Mark D. Tyson II, MD, MPH

  Urology

  •

  Mayo Clinic Comprehensive Cancer Center

  One of the exciting studies we're doing at Mayo Clinic uses a urinary biomarker from a urine sample to identify recurrence without the need for cystoscopy.

  Source
• 

  Joseph Liao, MD

  Urology

  •

  Stanford Medicine, Department of Urology

  Our test can detect minimal residual disease non-invasively after bladder cancer treatment, while accounting for mutations present in normal urothelium that has complicated prior studies. For the first time, we were able to distinguish patients likely cured by BCG from those cured by surgery.

  Source
• 

  Max Kates, MD

  Urologic Oncology

  •

  Johns Hopkins Medicine, Brady Urological Institute

  UCA1 is showing promise as a new way to identify dangerous bladder cancers in a noninvasive way. It could also help monitor patients over time, and help us detect shifts from low to high-grade disease sooner.

  Source
• 

  Michelle Higgins, MD

  Urology

  •

  Johns Hopkins Medicine, Brady Urological Institute

  We tested urine from 50 patients using a lab method called RNA in situ hybrid­ization (RISH) to detect UCA1 in urine samples. We found that RISH detected high-grade bladder cancer in 67 percent of cases — much better than cytology (looking at bladder cells in urine) alone, which detected just 34 percent. When both tests were used together, detection improved to 78 percent.

  Source